Law & policy

Latest content

CNIPA's draft patent examination guidelines: what is coming down the pipeline?

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

One-on-one with KIPO commissioner Kim Yong Rae

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

Benchmarking the IP5

Featured in Special Report 2021 Q4: IP5 insights

29 November 2021

Mainstream focus on supply chains will impact US patent fights

Saturday Opinion: Inflation and goods shortages are making the supply chain an everyday conversation topic this holiday season, and that is already influencing arguments over IP enforcement

27 November 2021

Balance and clarity are the top US policy priorities for patent leaders

On the sidelines of IPBC Global last week, IP executives from Xperi, Hewlett Packard Enterprise, IBM, Valo Health and Aon IP Solutions identified what they see as the most pressing issues

25 November 2021

“Every crisis brings about innovation" – how the vaccine race is transforming biopharma IP

From greater respect for researchers to a fresh focus on compulsory licences, IAM’s Global Leaders share their views on how the life sciences space has been changed by the quest for covid-19 vaccines

24 November 2021

How to deal with China's new crackdown on bad-faith patent filings and other examination changes

The Long Read: New guidelines in the works at the CNIPA will continue the fight against 'irregular' applications, make utility models harder to get and heighten the risk of litigation in the software space, write Aaron Wininger of Schwegman Lundberg & Woessner, PA and Austin Chang of Beijing East IP

24 November 2021

US patent system due for a mid-course correction, says IBM's IP business head

Bill LaFontaine says the current challenging licensing environment stems not only from legal and policy factors, but also from a widespread cultural shift that has normalised infringement

22 November 2021

Chinese law should do more to encourage joint patent licensing, says adviser to country's IP courts

Professor Cui Guobin says that both patent owners and implementers want greater clarity around pools and antitrust law

22 November 2021

Why CNIPA could be the go-to venue for Chinese patent linkage plaintiffs

Pharma patentees face difficult choices under the country’s new early dispute resolution framework

19 November 2021

Get unlimited access to all IAM content